Uma Sinha
CIK 1742587 · Chief Scientific Officer · last filed 2026-05-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.10M
Companies
3
Total Filings
22
Lifetime Open-Market Net
-$3.27M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Recent Filings · Page 2 of 3
22 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-10-30 | Eidos Therapeutics, Inc. (EIDX) Delisted | Sell (S) | −5,000 | -$362.1K | EDGAR |
| 2020-10-02 | Eidos Therapeutics, Inc. (EIDX) Delisted | Sell (S) | −5,000 | -$261.7K | EDGAR |
| 2020-08-18 | BBIO | Exer (M) | +468 | $0 | EDGAR |
| 2020-06-05 | Eidos Therapeutics, Inc. (EIDX) Delisted | Grant (A) | +444 | $18.5K | EDGAR |
| 2020-06-03 | BBIO | Grant (A) | — | $0 | EDGAR |
| 2020-05-21 | BBIO | Grant (A) | +1,523 | $0 | EDGAR |
| 2019-12-20 | Eidos Therapeutics, Inc. (EIDX) Delisted | Sell (S) | −12,500 | -$773.8K | EDGAR |
| 2019-09-27 | Eidos Therapeutics, Inc. (EIDX) Delisted | Sell (S) | −2,500 | -$96.0K | EDGAR |
| 2019-07-29 | Eidos Therapeutics, Inc. (EIDX) Delisted | Mixed | −3,231 | -$159.4K | EDGAR |
| 2019-07-03 | BBIO | Buy (P) | +14,000 | $238.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.